Wyniki wyszukiwania:

Erectile dysfunction can affect all age groups. Numerous physical and emotional risk factors may contribute to the problem. These risk factors can range from chronic diseases and medications to psychological factors. In the U.S. alone, it has been estimated that 18 to 30 million men suffer from erectile dysfunction. This number has increased significantly as awareness of the disorder has heightened. Researchers and health care professionals now have a better understanding of what causes erectile dysfunction and the effective medications and non-medication treatments used to treat the...

A concise, up-to-date review of the many new therapies available for the treatment of benign prostatic hypertrophy (BPH). The authors concisely evaluate the latest minimally invasive therapies, as well as time-tested surgical treatments, and review the medical therapies for BPH, namely a-adrenergic antagonists, 5-a reductase inhibitors, and their therapeutic combinations. Additional chapters examine the pathophysiology and natural history of BPH, its epidemiology, and the urodynamic evaluation of lower urinary tract symptoms. A perfect reference source for the practicing urologist seeking...

Benign prostatic hyperplasia and the resulting lower urinary tract symptoms is a major part of almost any urologist's clinical practice. Due to the high prevalence of the disease in our aging population, new concepts and treatments are constantly entering the marketplace. Differences in patient preferences and desired outcomes require the practicing urologist to understand not only the pathophysiology of the disease but how specific treatments may be better suited for some patients and not others. This issue will address the current concepts and treatments available to urologists.

A concise, up-to-date review of the many new therapies available for the treatment of benign prostatic hypertrophy (BPH). The authors concisely evaluate the latest minimally invasive therapies, as well as time-tested surgical treatments, and review the medical therapies for BPH, namely a-adrenergic antagonists, 5-a reductase inhibitors, and their therapeutic combinations. Additional chapters examine the pathophysiology and natural history of BPH, its epidemiology, and the urodynamic evaluation of lower urinary tract symptoms. A perfect reference source for the practicing urologist seeking...